Study identifier:D8480C00022
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A phase 1, open label, dose seeking study of AZD2171 given daily orally in combination with selected chemotherapy regimens in patients with advanced incurable non-small cell lung cancer or colorectal cancer
Oncology
Phase 2
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
-
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|